Monooxygenase: Potential Drug Targets and Biomarkers (P5830)

Target Name: Amino acid hydroxylase

NCBI ID: P5830

Amino acid hydroxylase

Other Name(s): Monooxygenase | AAAH

Monooxygenase: Potential Drug Targets and Biomarkers

Amino acid hydroxylase (nonspecified subtype) (Monooxygenase), also known as monooxygenase or 2-oxoglutarate dehydrogenase, is an enzyme involved in the metabolism of amino acids, particularly glutamate and its precursors. This enzyme catalyzes the conversion of glutamate to gamma-aminobutyrate, which is then converted to gamma-aminobutyrate, a key step in the citric acid cycle.

The nonspecific subtype of amino acid hydroxylase (Monooxygenase) is a widely expressed enzyme in various organisms, including bacteria, archaea, and eukaryotes. It is involved in various cellular processes, including metabolism, stress response, and signaling pathways.

Drug targets and biomarkers for Monooxygenase

Monooxygenase has been identified as a potential drug target in the treatment of various diseases. Its involvement in the citric acid cycle and its role in the metabolism of essential amino acids make it an attractive target for interventions aimed at modulating cellular metabolism.

One of the potential benefits of targeting Monooxygenase is its ability to modulate cellular metabolism and reduce inflammation. The citric acid cycle is a central player in the production of reactive oxygen species (ROS), which can contribute to cellular damage and inflammation. By modulating the production and degradation of ROS, Monooxygenase can have a negative impact on cellular stress and inflammation.

In addition, Monooxygenase has been implicated in the regulation of cellular signaling pathways, including the TOR signaling pathway. This pathway regulates cell growth, metabolism, and stress response, and is a key target for many therapeutic interventions. By modulating the activity of Monooxygenase, researchers can potentially interfere with TOR signaling and improve cellular growth and metabolism.

Another potential application of Monooxygenase as a drug target is its role in the metabolism of tryptophan, a critical amino acid involved in the synthesis of neurotransmitters, such as serotonin and dopamine. Monooxygenase has been shown to play a role in the metabolism of tryptophan, and Alterations in its activity have been linked to various neurological and psychiatric disorders. Targeting Monooxygenase with drugs that modulate its activity could provide new treatments for conditions such as depression, anxiety, and psychosis.

Monooxygenase is also a potential biomarker for certain diseases. The production of ROS and the activity of Monooxygenase have been shown to be altered in various diseases, including cancer, neurodegenerative disorders, and chronic obstructive pulmonary disease (COPD). By detecting changes in Monooxygenase activity , researchers can potentially use Monooxygenase as a diagnostic or therapeutic target in these diseases.

Targeting Monooxygenase

There are several potential strategies for targeting Monooxygenase, including inhibition of its activity with small molecules, modulation of its expression, and alteration of its cellular localization.

One approach to targeting Monooxygenase is the use of small molecules that inhibit its activity. Many of these molecules have been identified as potential drug targets for other enzymes, including kinases, inhibitors and antagonists. For example, inhibitors of the Monooxygenase enzyme have been shown to have a negative impact on cellular metabolism and to reduce the production of ROS. One such inhibitor is a derivative of the amino acid alanine, which has been shown to inhibit Monooxygenase activity in cell culture assays.

Another approach to targeting Monooxygenase is the use of modulators that alter its expression. This can be achieved through genetic modification, such as the introduction of a null gene or the addition of a wild-type gene to the genome. Modulators that alter Monooxygenase expression have has been shown to have a positive impact on cellular metabolism and to modulate the activity of Monooxygenase.

A third approach to targeting Monooxygenase is the use of drugs that alter its cellular localization. This can be achieved through inhibitors of

Protein Name: Amino Acid Hydroxylase (nonspecified Subtype)

The "Amino acid hydroxylase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Amino acid hydroxylase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets